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The Global Programme to Eliminate Lymphatic Filariasis: History and
achievements with special reference to annual single-dose treatment with
diethylcarbamazine in Samoa and Fiji
Eisaku Kimura
Abstract: Diethylcarbamazine (DEC), first introduced in 1947, was shown to have strong efficacy and safety for
treatment of human lymphatic filariasis, which is caused mostly by a species Wuchereria bancrofti. Many studies
to optimize the dosage and treatment schedule of DEC followed, and, based on the results, control programs with
various regimens were implemented in different endemic areas/countries. By the mid 1970s, with endorsement by
the WHO Expert Committee on Filariasis (3rd report, 1974), the standard DEC regimen for W. bancrofti infection
in mass treatment had been established in principle: a total dose of 72 mg/kg of body weight given in 12 divided
doses, once weekly or monthly, at 6 mg/kg each. Not long after the committee report, the efficacy of annual
single-dose treatment at 6 mg/kg, which is only one twelfth of the WHO-recommended dose in a year, was re-
ported effective in French Polynesia (study period: 1973-78), and later in Samoa (study period: 1979-81). These
results were published between 1978 and 1985 in the Bulletin of WHO but received little attention. In the mid
1980s, the efficacy of ivermectin, the first-choice drug for onchocerciasis, against lymphatic filariae came to light.
Since the effect at a single dose was remarkable, and often better than DEC, it was predicted that the newly intro-
duced drug would replace DEC. Treatment experiments with ivermectin increased quickly in number. Meanwhile,
annual single-dose mass drug administration (MDA) with DEC at 6 mg/kg was under scrutiny in Samoa and Fiji.
In the early 1990s, the Samoan study, which covered the entire population of 160,000 with 3 annual MDAs, re-
ported a significant reduction in microfilaria (mf) prevalence and mean mf density, while in Fiji, the efficacy of 5
rounds of annual MDA (total dose, 30 mg/kg) was shown to be as effective as 28 multi-dose MDA spread over 2
years (6 weekly plus 22 monthly treatments at 5 mg/kg; total dose, 140 mg/kg). Several additional studies carried
out in Samoa in relation to the annual single-dose MDAs revealed that low density mf carriers, who have a very
low mf count of 1-20/ml of venous blood, could not play a significant role in filariasis transmission.
From around 1990, studies on spaced low-dose DEC treatments and various types of combination chemother-
apy with DEC and ivermectin increased. Albendazole, a well-known anti-intestinal helminths agent, was later
added to the combination. The main findings of these studies with W. bancrofti are: (i) a single dose of DEC at 6
mg/kg reduced mean mf density by ca. 90% 1 year after treatment; (ii) the same dose could damage/kill adult
worms; (iii) a single dose of ivermectin at ca. 400 µ g/kg was more effective than DEC in reducing mf density dur-
ing the first year and was similarly or less effective in the second year; (iv) ivermectin probably could not kill adult
worms; (v) a single combined dose of albendazole (400 mg) and DEC (6 mg/kg) was effective to reduce mf density
by 85 to nearly 100% 12-24 months after treatment; and (vi) ivermectin or albendazole included in the combination
chemotherapy produced “beyond-filariasis” benefits: clearance/reduction of intestinal helminths, and, additionally,
in the case of ivermectin, skin-dwelling ectoparasites.
The Global Programme to Eliminate Lymphatic Filariasis (GPELF) started its worldwide activities in 2000,
with the target of elimination by 2020. The basic strategy is to conduct annual single-dose MDAs for 4-6 years. In
2000-2007, a minimum of 570 million individuals were treated in 48 of 83 endemic countries. The drugs used are
DEC 6 mg/kg plus albendazole 400 mg in most countries, or ivermectin 200-400 µ g/kg plus albendazole 400 mg
particularly in onchocerciasis endemic countries inAfrica. (MDAs with DEC alone had been used in India.)
The GPELF achieved impressive results in terms of parasitological cure/improvement, clinical benefits, social
and economic impacts, etc. However, the most impressive result of all was the programme’s success in mobilizing
hundreds of millions of local people, who not only took drugs but many of them actively supported MDAs as drug
distributors and volunteers. Beyond filariasis, the role people can play in supplementing rural health services is
now a topic of discussion and a source of hope for a new sustainable system.
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annual single-dose, mass drug administration, Samoa, Fiji
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̍ ̓A. Introduction
a-1. Parasite and disease
Human lymphatic filariae, which are characterized by
the parasitism of their adult worms in the lymphatic system,
include 3 species, Wuchereria bancrofti, Brugia malayi and
Brugia timori. Female adults reproduce offspring or micro-
filariae (mf) which are carried into blood circulation by the
lymph flow and accumulate in the lungs. Mf are released
from the lungs into the circulation at night (nocturnal perio-
dicity of mf), synchronizing with the circadian biting cycle
of mosquitoes that transmit the parasite between humans.
In some Pacific islands, where Aedes mosquitoes bite hu-
mans in the daytime, the release from the lungs is mainly in
the afternoon (diurnally subperiodicity). The detection of
mf in blood is a basic method of diagnosis. After being in-
gested by mosquito vectors, mf develop to the infective
stage of larvae in about 10-14 days. When mosquitoes with
infective larvae bite humans, filarial parasites have an op-
portunity to enter the host. Infective larvae, males and fe-
males, penetrate the human skin, migrate in the body and
reach the lymphatic system where they mature, mate and re-
produce mf in about 6-12 months after skin invasion. Adult
worms will damage and dilate lymphatic vessels, and cause
lymphostasis often in the lower limb and around the testes
and kidney. This is the basic pathology of chronic filariasis
characterized by lymphedema, hydrocele, and chyluria.
Lymphedema often triggers secondary bacterial infections
resulting in acute fever attacks (acute dermatolymphan-
gioadenitis [1]), which aggravate lymphedema/inflamma-
tion. In some people, the edematous skin gradually thick-
ens, hardens and may grow to wart-like lesions. The word
‘elephantiasis’refers to this condition with the often serious
deformities that have caused enormous suffering among af-
fected people worldwide for thousands of years (Fig. 1) [2].
a-2. Epidemiology and global efforts to eliminate lym-
phatic filariasis
The total number of lymphatic filariasis cases in the
world, as estimated in 1996 [3], was 120 million, about
90% of which were caused by W. bancrofti. The total fig-
ure includes 16 million lymphedema (including elephantia-
sis) and 27 million hydrocele cases, the rest being cases
with microfilaremia only. The infection was more prevalent
among males, and adults. By region/country, India and sub-
Saharan Africa had more than 40 million cases each, fol-
lowed by otherAsia and Islands (ca. 20 mil.) and China (ca.
10 mil.). With the swollen leg and/or scrotum, lymphatic fi-
lariasis was ranked as the 4th leading cause of permanent
and long-term disability [4]. Most of the patients have been
neglected and suffer from mental distress, social isolation,
and economic misery due to the stigma of the disfiguring
disease [5]. The estimated disability-adjusted life years
(DALYs) lost in 1999 was 4.92 million [6]. As for eco-
nomic loss, in India alone, the cost of treatment for acute fe-
ver attacks and chronic symptoms reached an estimated
US$ 31.1 million per year, and the loss of productivity US$
811 million per year [7].
These gloomy statistics have changed rapidly for the
better since the Global Programme to Eliminate Lymphatic
Filariasis (GPELF) started in 2000 (details in Section F).
The Global Alliance to Eliminate Lymphatic Filariasis
(GAELF) was formed the same year to support the unprece-
dented global program. The alliance includes health minis-
tries of endemic countries, UN agencies (especially WHO
as the secretariat), the private sector, NGDOs, academia,
and government bodies (including JICA). Particularly note-
worthy are the contributions of two pharmaceutical compa-
nies: GlaxoSmithKline donates albendazole free of charge
and Merck & C., Inc. ivermectin. Both drugs are essential
for the Mass Drug Administration (MDA) carried out annu-
ally in endemic countries. In 2007, 48 out of 81 endemic
countries conducted MDAs, and 546 million people in the
world were treated for lymphatic filariasis. The same year,
China declared the elimination of filariasis, which was fol-
lowed by Korea’s declaration in 2008 [8].
B. The “new” anti-filarial drug diethylcarbamazine
(DEC): Early studies to find the optimal dosage
b-1. Trials with multi-dose treatment
The anti-filarial effect of 1-diethylcarbamyl-4-
methylpiperazine hydrochloride (DEC hydrochloride) was
first reported in 1947 by Hewitt et al. [9] using naturally ac-
quired filarial parasites in cotton rats (Litomosoides carinii)
and dogs (Dirofilaria immitis) . T h es a m ed r u gw a st r i e df o r
human bancroftian filariasis and its microfilaricidal and
possible adulticidal effects were confirmed the following
year [10]. A series of experimental treatments was con-
ducted using DEC citrate for DEC hydrochloride to deter-
mine suitable dosage and treatment schedule. Many impor-
tant studies were carried out in the South Pacific islands,
where more than 10,000 American soldiers suffered clinical
filariasis due to diurnally subperiodic W. bancrofti during
World War II [11].
In American Samoa, 5 different multi-dose trials with
DEC (3-9 mg/kg of body weight per day for 7-30 days, to-
tal dosage 21-270 mg/kg) confirmed rapid microfilaricidal
effects, but the treatments could not prevent the reappear-
ance of mf in 2-year follow-up studies (reported in 1953
[12]). Using 111-175 mf positives, Mahoney & Kessel [13]
reported in 1971 that DEC given at 6 mg/kg daily for 6 days
̍ ̔resulted in 32% persistence (rate of mf positive 1 week after
treatment) and that the recurrence rate was 24% (rate of mf
reappearance within 1 year of treatment). In this study, the
diagnosis of infection was made by the detection of mf in
20 µ l capillary blood obtained by the finger-prick (F-P)
method.
In Fiji, Manson-Bahr (1952) [14] conducted treatment
experiments with Hetrazan (DEC) at 100-300 mg daily for
15 to over 70 days and concluded that treatment must be
continuous for at least two months. This conclusion was
based on a finding that, even after multi-dose treatments
cleared mf in 20 µ l of F-P blood, mf were still positive
when 1 ml of venous blood was examined by Knott’s
method. Burnet & Mataika (1961) [15] administered 6
weekly doses of DEC at 400 mg (ca. 5-8 mg/kg) each and
repeated the same regimen half a year later (total dosage
4,800 mg). The treatment reduced mf rate, determined with
60 µ l of F-P blood, from 12.2% to 2.7%. However, they
noted that over 40% of mf negatives (who had been positive
before treatment) were in fact positive by Knott’s method
Fig. 1 Chronic symptoms of lymphatic filariasis
A: An Egyptian relief from Queen Hatshepsut’s temple, Luxor, depicting the Princess of Punt, a
possible elephantiasis case. (The Queen’s reign: 1503-1482 B.C.); B and D: Elephantiasis of the
legs and scrotum, described some 1,000 years ago in “Strange Diseases Picture Scroll.” (Kyoto
National Museum, Japan); C: Huge elephantiasis of the scrotum, painted by Hokusai Katsushika
(1760-1849). Manga in the Edo era of Japan. {From Ref. [2], courtesy of Prof.Yoshihito Otsuji}
̍ ̕using 1 ml of venous blood.
In French Polynesia, Kessel (1957) [16] compared 3
different dosages and reported that 6 mg/kg once a month
for 24 months showed the best result in terms of mf preva-
lence and density (mf/20 µ l of blood) reductions. In Japan,
among various dosage schemes tested by different workers,
Sasa (1976) [17] stressed the importance of the size of total
dosage given, rather than the schedule of daily, weekly or
monthly treatment, and recommended a total dosage of 72
mg/kg at 6 mg/kg daily for 12 days.
The WHO Expert Committee on Filariasis analyzed
the accumulated data on DEC dosage and reported in 1967
[18] that “an adequate amount seems to be a total dose of
about 72 mg of diethylcarbamazine citrate per kg body
weight”. Spaced doses of 6 mg/kg once a week or once a
month (12 times) were preferred to daily doses to reduce
adverse reactions. The next WHO Expert Committee Re-
port (1974) [19] confirmed the same total dose of 72 mg/kg
for W. bancrofti infections and 30-40 mg/kg for B. malayi
infections. Daily treatment was considered impractical for
mass treatment. In 1984, the 4th Committee Report [20] re-
iterated the same total dosage for W. bancrofti.
b-2. Effect of low-dose treatments: results from a “minor-
ity” group
Several studies with W. bancrofti reported the remark-
able effectiveness of DEC at low dosages. Rachou & Scaff
(1958) in Brazil (quoted by Hawking, 1962 [21]) reported
that only one dose at 6 mg/kg reduced the mf prevalence
rate from 100% (pretreatment level) to 62%, and mf density
by 91.4% when assessed 12 months after treatment. The
authors recommended annual or biannual mass treatments
without prior blood tests for mf. In Gambia, McGregor &
Gilles (1960) [22] observed that a total dose of 12.5 mg/kg
(2.5 mg/kg daily for 5 days) reduced microfilarial load by
90-98% 43 months after treatments and left the noteworthy
comment that “mass-treatment campaigns aimed at dosing
all inhabitants at spaced intervals (2-4 years) might in the
long run prove to be the most effective and economical
way.” Nearly 2 decades later, in French Polynesia, Laigret
et al. (1978) [23] reported that DEC 6 mg/kg (400 mg for
males and 300 mg for females) given once per year for 3
years successfully reduced the mf rate from 100% (pretreat-
ment level) to 12% and the average mf density from 15 per
20 µ l of blood to 0.3. The annual single-dose treatment was
applied to ca. 50,000 people for 4 years and succeeded in
reducing the mf prevalence from 4.4% to 1.9%. In practice,
not all of the people took 4 doses; the result was obtained
with the average of 2.76 doses in 4 years [24].
It is surprising to find that the dosages recommended
for DEC treatment differed so widely in range. Under-
standably, researchers seemed to focus more on the cure of
infection in the early stage of dosing trials. Due to the reap-
pearance of mf after treatments, adulticidal effect was con-
sidered a key issue in judging the efficacy of a drug. Thus,
the necessity of multi-dose treatment with a high total dos-
age must be stressed. On the other hand, it seems that a
small number of researchers, especially those working in
less-developed settings, paid more attention to the applica-
bility of a treatment scheme. Also, the experience of diffi-
culty in conducting multi-dose treatments and the recogni-
tion of adverse effects in such treatments must have con-
vinced researchers to accept regimens not ideally effective
but operationally feasible. The realization that very light in-
fections had been missed previously when conventional
blood tests (with 20-60 µ l of F-P blood) were used for diag-
nosis called for a more suitable means of large-scale mass
treatment. In 1984, the WHO Expert Committee on Filaria-
sis, for the first time, mentioned the effectiveness of yearly
treatments at 6 mg/kg [20].
C. Filariasis control in Samoa and Fiji with annual
single-dose MDA using diethylcarbamazine
c-1. Countries and their filariasis situations
Samoa, an independent country in the South Pacific,
had a population of 160,000 (1990) in the 2 main islands of
Upolu and Savaii. Diurnally subperiodic W. bancrofti,
transmitted by Aedes polynesiensis and Aedes samoanus,i s
endemic. The prevalence study in 1965 revealed a mf rate
of 19.1% (n = 10,129) by the 20 µ l F-P blood smear method.
The first nationwide MDA in 1965/66 using DEC (5 mg/kg
once a week for 6 weeks, followed by the same dosage once
a month for 12 months) reduced the mf rate to 1.63% (n =
42,697) in 1967, and the second MDA in 1971 (6 mg/kg
once a month for 12 months) further reduced the rate ʕ as-
sessed by the 60 µ l F-P method in 1972 ʕ to 0.24% (n =
6,361). Despite continuing treatment of known mf positives,
the prevalence increased gradually, and in 1979, reached
3.8% (n = 8,385) by 60 µ l blood smear and 4.5% (n =
8,385) by the nuclepore filtration method using 1 ml of ve-
nous blood (1 ml NP method). The situation was alarming,
because mf rate (by 1 ml NP method) of adult males aged
ʾ30 years had already reached the 20% level [25].
Fiji is the largest island country in the region, with a
total population of 726,400 (1990) scattered over 100 is-
lands. The two main islands are Viti Levu and Vanua Levu.
Diurnally subperiodic type W. bancrofti, transmitted by Ae.
polynesiensis, Ae. pseudoscutellaris and several other mos-
quito species, is endemic. In 1958, the mf prevalence deter-
mined by 60 µ l F-P method in the delta area of the Rewa
River, Viti Levu, was 12.2% (n = 1,200), which decreased
̎ ̌to 2.7% (n = 1,123) in 1959 after 2 rounds of MDA with
DEC (400 mg once, 6 times weekly). However, by 1963,
the rate increased to a level of 5% [26]. The 1968-69 stud-
ies in Taveuni and Koro islands, and Vanua Levu revealed a
mf prevalence of 23% (n = 947) and 13% (n = 3,538) by the
60 µ l F-P method, respectively (computed from the data by
Mataika et al., 1971 [27]). A nationwide MDA campaign
was commenced in 1969 using DEC at 5 mg/kg weekly for
6 weeks, followed by 22 monthly treatments (totally 28
doses, 140 mg/kg). The whole country was covered in 5
stages, and the campaign, which reached completion in
1975, successfully reduced the mf prevalence to 1% or less,
but subsequent blood surveys suggested a gradual increase
in infection [28]. The surveys in 1983-84 in the 2 remote
islands of Lau and Rotuma revealed mf rates of 7.9% (n =
2,329) and 21.2% (n = 1,689) by the 60 µ l F-P method, re-
spectively [29]. In a 1985 survey in Kadavu island, the mf
rate was 6.9% by the same method (n = 4,686) [30].
c-2. WHO/Samoa Filariasis Research Project: Confirma-
tion of efficacy of annual single-dose treatment
In 1976, when the WHO/Samoa Filariasis Research
Project started, it had become standard practice in the treat-
ment of bancroftian filariasis to give a total DEC dose of 72
mg/kg in 12 treatments at 6 mg/kg each. However, difficul-
ties in multi-dose treatment had been encountered in many
endemic countries. Especially in Samoa, where a year-long
multi-dose MDA was conducted twice in 1965/66 and 1971
utilizing limited health resources, the government was re-
luctant to repeat the procedure. In the midst of this situ-
ation, a report from French Polynesia that annually spaced
single-dose DEC at 6 mg/kg was effective in reducing mf
rate and density [23] brought encouraging news. Although
the regimen was not popular in those days, the Research
Project in Samoa decided to evaluate the efficacy of DEC
single dose 12 months after treatment.
In the study in 1979-81, a single DEC dose of 4 mg/kg,
6 mg/kg or 8 mg/kg was administered to mf positive per-
sons and the change in mf was assessed at 12 months by the
1 ml NP method (Table 1). The cure rate (% mf negative
after treatment) was 29.4%, 53.7% and 40.0%, and the %
decrease in geometric mean mf count was 81.5%, 94.4%
and 93.5%, respectively for 4 mg/kg, 6 mg/kg and 8 mg/kg
regimens. There was no significant difference among the
cure rates, but the % decrease obtained with 4 mg/kg regi-
men was less than that of the 6 mg/kg or 8 mg/kg regimen
(P < 0.01). Side reactions were studied by questioning peo-
ple between 5 and 15 days after treatment. The occurrence
of reactions (all types combined) was significantly higher in
the 8 mg/kg regimen (77.9%) than in the other regimens
(57-59%). It was concluded that annual single-dose DEC
treatment at 6 mg/kg was suitable for the nationwide treat-
ment for filariasis [31]. In 1981, upon completion of the
study, the government of Samoa in collaboration with the
Western Pacific Regional Office of WHO decided to imple-
ment a national MDA program based on this treatment.
c-3. Nationwide MDA in Samoa with once-a-year treat-
ment: Long-term efficacy
A national MDA using a single dose of DEC at 6 mg/
kg was started in 1981. All Samoans, except infants under
the age of 1 year, pregnant women, sick people, and the
very old, were the targets. After completion of the census
in every village and town in the country with assistance of
village Women’s Committees, 3 MDAs were carried out un-
der the supervision of medical staff by members of
Women’s Committees in 1982, 1983, and 1986, with a
treatment coverage of 86.3%, 83.8% and 82.6%, respec-
tively. The total population in 1986 was 159,199. The
evaluation blood surveys were carried out 4 times, before
and after each MDA, using 60 µ l blood smears from some
9,600-13,700 people in 26-34 villages on each occasion.
The MDAs reduced the mf prevalence gradually from 8.0%
to 3.8% (52% reduction) in males, and from 3.2% to 1.3%
(59% reduction) in females. The mf densities (geometric
mean of positive counts per 60 µ l) decreased from 23.1 to
9.1 (61% reduction) in males and from 14.6 to 9.4 (36% re-
duction) in females. The change in mf prevalence is sum-
marized in Fig. 2, before and after 3 MDAs according to
sex and age [32].
The transmission potential or infectivity index (%) of
total population (IIT), which is an estimated mosquito in-
Table 1. Comparison of the effects of 3 different DEC dosages
given as a single dose and assessed 12 months after
treatment
Dosages
4 mg/kg 6 mg/kg 8 mg/kg
No. examined (mf carriers) 51 41 45
No. mf negative after treatment
(% cure rate)
15
(29.4)
22
(53.7)
18
(40.0)
Decrease in mf count, expressed as
mean of log (mf +1)
Pre-treatment (A) 2.117 2.003 2.198
Post-treatment (B) 1.384 0.751 1.010
Change 0.733 1.251 1.188
% decrease
ˎ 81.5 94.4 93.5
ˎ Calculated as 100 x [antilog (A) - antilog (B)]/antilog (A).
{Source: Partially adopted from Ref. [31]}
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fection rate [33], was reduced from 2.18 before MDA to
0.67 (70% reduction) after 3 MDAs. Entomological studies
were also conducted at Vailu’utai village on Upolu Island.
A total of 1,758 Ae. polynesiensis were dissected before
MDA and 5,206 after the 2nd MDA. The results revealed a
decrease in mosquito infection rate from 0.97% to 0.06%
and the infective rate (% of mosquitoes having the infective
stage of larvae) from 0.28% to 0.02% [32].
These findings indicated the remarkable long-term ef-
ficacy of annually spaced single-dose MDAs, given in fact 3
times in 6 years, and at the same time, the feasibility of a
nationwide control program in which people are the major
players.
c-4. Fiji study for confirmation of efficacy of 5 rounds of
annual single-dose treatment with DEC: comparison
with 28 multi-dose MDA
Mataika et al. (1993) [34] carried out an extensive
study comparing DEC efficacy between 5 annual single-
dose MDAs at 6 mg/kg (total 30 mg/kg) and very intensive
28-dose MDA (5 mg/kg once a week for 6 weeks, then
monthly for 22 months; total 140 mg/kg). The results are
shown in Fig. 3 [35]. The annual scheme reduced the mf
rate year by year from 6.5% before treatment (average of
males and females) to 0.9% after 5 treatments (87% reduc-
tion), while in the multi-dose scheme, the rate dropped
sharply from 11.6% to 0.8% in 1987, and to 0.9% at 5 years
(93% reduction). However, without treatment for more
than 2 years after completion of the intensive 2-year regi-
men, a slight but significant increase in mf rate was ob-
served in 1990/91 compared with the previous year. This
indicates the advantage of continued annual doses rather
than a concentrated multi-dose treatment. This study recon-
firmed the effectiveness of annual single-dose MDAs. It
was obvious that the annual scheme was much easier and
more practical than the multi-dose scheme.
D. Low-density microfilaremia in Samoa and its signifi-
cance in filarial transmission
d-1. What is low-density microfilaremia?
There are mf densities that are too low to be detected
by conventional blood smears with 20-60 µ l of F-P blood.
The employment of nuclepore/millipore filtration of 1 ml
venous blood has facilitated the detection of low density mf
carriers. Low mf density was defined variously by re-
Fig. 2 Change in microfilaria prevalence before and after 3
annual single-dose MDAs with DEC at 6 mg/kg, ana-
lyzed by sex and age group (study in Samoa)
{Figure redrawn from Ref. [32]}
Fig. 3 Comparison of 2 MDA schemes with DEC: 5 rounds of
annual single-dose treatment at 6 mg/kg (Treat. 1) and
28-dose treatment at 5 mg/kg given weekly for 6 weeks
and monthly for 22 months (Treat. 2). Each arrow indi-
cates a single treatment. {Figure redrawn from Ref. [35]}
̎ ̎searchers. A mf range of 1-10 mf/ml was cited but often
proved inconvenient for analytical studies as not many cases
fell into this category. Comparing the 60 µ l F-P method
and 1 ml nuclepore filtration method, 1-20 mf/ml was de-
fined as low-density microfilaremia (l.d.m.) for studies in
Samoa [36]. The prevalence of l.d.m. in all mf positives
was 23.6% (90/381), which led to an estimate of 1,700 low-
density mf carriers in 1979 throughout the country. L.d.m
was proportionally more frequent in villages with lower mf
prevalences and in people < 20 years of age. By sex, there
was no difference.
Since low-density mf carriers were recognized to oc-
cupy a substantial proportion of all mf carriers in Samoa,
and Ae. polynesiensis were known to ingest more mf than
estimated (up to 4.7 times) while having a blood meal on
low-density mf carriers [37], the significance of l.d.m. as a
source of transmission was seriously discussed, especially
because it was suspected that annual single-dose DEC
would not exert a sufficient adulticidal effect and therefore
produce more low-density carriers than multi-dose treat-
ment.
d-2. Significance of low-density mf carriers in filariasis
transmission: Quantitative assessment
Based on the mosquito “infectivity index” concept pro-
posed by Sasa [33], the significance of l.d.m. in transmis-
sion can be determined by estimating the proportion of
mosquito infectivity produced by the l.d.m. group as com-
pared to the total mosquito infectivity produced by all levels
of mf carriers in an endemic community. Assuming that all
people are exposed evenly to mosquito bites, the latter can
be computed as follows:
Total mosquito infectivity = Σ (infection rate when mosqui-
toes feed on a carrier with mf density of k) x (No. of carri-
ers with mf density of k in a community)
where k is from 1 to the maximum mf density (/1 ml of ve-
nous blood) observed in the community. Mosquito infectiv-
ity produced by low-density mf carriers will be obtained us-
ing the same formula with k value from 1 to 20.
To study the rate of mosquito infection, Samarawick-
rema et al. (1985) [37] conducted a detailed transmission
experiment using Ae. polynesiensis, a main vector in Samoa,
and 14 mf carriers with different mf densities ranging from
0 to 5,290 mf/ml. The results showed that the percentage of
mosquitoes infected and the average number of larvae
found in each infected mosquito were directly proportional
to the mf densities in the carrier at the time of feeding.
Based on the data from this transmission experiment, it was
possible to obtain theoretical mosquito infection rates when
mf carriers with different mf densities were blood sucked
by mosquitoes [36]. To estimated the numbers of mf carri-
ers with certain mf densities, a negative binomial distribu-
tion was fitted following the method of Pichon et al. (1980)
[38] to the 1979 mf data from Samoa (n = 358 mf positives)
[25].
The computation of mosquito infectivity is shown in
Table 2. The infectivity produced by l.d.m. was 251.2 (B)
and that by all levels of mf density was 11645.8 (A), and
the contribution of l.d.m. to the total (B)/(A) was 0.0216 or
only 2.16%. This would suggest a minor role of l.d.m. in
the transmission of filariasis in Samoa [36].
E. Re-evaluation of low-dose DEC treatment, introduc-
tion of new drugs and their combination therapy
e-1. New evidences supporting the efficacy of low-dose
DEC treatments
After around 1990, a variety of low-dose DEC treat-
ments were tested in various countries where W. bancrofti is
endemic. In Tahiti, a single dose of 3 mg/kg was reported
effective in reducing geometric mean mf count by 95%
when assessed 180 days after treatment [39]; in Papua New
Guinea, 2 annual single doses at 6 mg/kg reduced the mf
rate from 41% to 17%, and mf density from 71 mf/20 µ lt o
20 [40]; in Brazil, the efficacy of 6 mg/kg given only once
was reported equally effective to 12 daily doses at 6 mg/kg
when measured 12 months after treatment, although the sin-
gle dose was significantly less effective than the multi doses
during the first 6 months [41]; and in Tanzania, two 6-
monthly treatments at 6 mg/kg reduced the geometric mean
mf intensity by 92.2%, while 12 daily doses at 6 mg/kg re-
duced it by 98.6%, when assessed 1 year after the start of
treatment. The former regimen was considered more suit-
able for MDAs than the standard 12-dose treatment [42].
The single dose treatment with DEC at 6 mg/kg was also
applied to Brugia malayi infections. In Kerala, India, 2 an-
nual mass treatments reduced the mf prevalence from 4.9%
to 1.2%, and the mean mf count by 81%. In addition, clini-
cal benefits such as a reduction in acute manifestations and
recent edema cases were reported [43].
A single dose DEC at 6 mg/kg reduced not only the mf
level by 90.5% but circulating filarial antigen by 39.7% 18
months after treatment, suggesting that the treatment was
effective against adult parasites [44]. Brazilian researchers
successfully studied the adulticidal effect of low-dose DEC
treatment by direct observation of live adults using ultra-
sonography. The adults live in a dilated lymph vessel in the
scrotal area, making a “nest” and moving actively. Amaral
et al. (1994) [45] named the movement “filaria dance sign”
([46] for video image). Norões et al. (1997) [47] reported
̎ ̏that within a week after treatment at 6 mg/kg single dose,
the dance sign became undetectable in 7 of 14 nests, and
scrotal nodules became palpable at each site of the 7 nests.
Biopsy specimens from these nodules revealed “nests” of
degenerating adults, confirming the adulticidal effect. A
separate histopathological study with DEC-induced nodules
reported that even a single dose of 1 mg/kg could damage
adult worms. However, it should be noted that, even after
repeated high dose DEC treatments, some worms in the
same nest remained intact [47, 48].
Fortunately, no drug resistance has been reported so far
with DEC.
e-2. Ivermectin as a new drug against lymphatic filariae
On the other hand, ivermectin, the drug of choice for
onchocerciasis that is also effective against intestinal
helminths and ectoparasites such as lice, was reported in
1988 [49] to be effective against W. bancrofti. Since it is
effective with a single oral dose at 25-200 µ g/kg, ivermectin
was cited as a candidate to replace DEC. The efficacy was
further confirmed: when assessed at 6 months, a single dose
at 21.3 µ g/kg and 126 µ g/kg reduced mf to 18.3% and
19.5% of the original levels, respectively, while 13 daily
DEC treatments (one 3 mg/kg dose, followed by 12 daily
doses at 6 mg/kg) reduced the level to 6.0% [50]. With a
Table 2. Mosquito infectivity produced by the low-density microfilaria (mf) carriers (B)
and all levels of mf carriers (A)
Microfilaria
density
(mf/ml)
Theoretical % of
infected fed
mosquitoes (I)
ˎ
Theoretical No. of mf
positive persons in each
mf density group (II)
(I) x (II)
1 0.492 13.214 6.5
2 1.152 8.584 9.9
-4 2.102 11.999 25.2
-6 2.842 8.774 24.9
-8 3.473 7.074 24.6
-10 4.032 6.000 24.2
-20 6.254 21.729 135.9
Subtotal 251.2 ...(B)
-30 7.985 15.076 120.4
-40 9.458 11.854 112.1
-50 10.766 9.892 106.5
-60 11.954 8.550 102.2
-70 13.052 7.565 98.7
-80 14.078 6.805 95.8
-90 15.045 6.198 93.2
-100 15.963 5.700 91.0
-200 23.456 41.077 963.5
-300 29.292 26.579 778.6
-400 34.259 19.642 672.9
-500 38.666 15.443 597.1
-600 42.673 12.589 537.2
-700 46.374 10.511 487.4
-800 49.834 8.925 444.8
-900 53.094 7.675 407.5
-1000 56.187 6.666 374.5
-2000 81.449 36.479 2971.2
-3000 100 (101.123) 13.242 1324.2
-4000 100 (117.869) 5.524 552.4
4001 100 (--) 4.634 463.4
Subtotal 11394.6
Total 358.000 11645.8 ...(A)
ˎ Estimated from log (Y + 1) = 0.5278 log X + 0.1739, where Y = % infected, X = mf density of a carrier.
{Source:Adopted from Ref. [36]}
̎ ̐higher dosage of 420 µ g/kg (20 µ g/kg at day 1 plus 400 µ g/
kg at day 5), the geometric mean mf density was reduced to
0.9% of the pretreatment level 1 year after treatment, while
DEC at 6 or 7 mg/kg reduced the mean to 9.3% (P < 0.006)
[51]. Another study with 420 µ g/kg of ivermectin reported
a mean mf reduction of 86.3% after 18 months, while it was
90.5% with a single dose of DEC at 6 mg/kg (P > 0.05). In
this study, the efficacy of ivermectin was much stronger
than DEC in the first 30 days after treatment, but by 18
months, the latter took over the lead and resulted in a
slightly higher reduction [44]. The stronger effect of DEC
as opposed to ivermectin in the second year was also re-
ported in Brazil [52]. To study adulticidal effect of iver-
mectin, Dreyer et al. (1995) [53] treated 15 W. bancrofti-
infected Brazilian men with a single dose of ivermectin at
400 µ g/kg and observed the filaria dance sign by ultrasound
for 3-9 months. Contrary to all expectations, there was no
observable change in the dance sign, and it was concluded
that ivermectin had no effect on adult worms.
e-3. Combination chemotherapies
Having two potent anti-filarial drugs, DEC and iver-
mectin, researchers tested the efficacy of their use in combi-
nation. More recently, the effectiveness of albendazole, an
established antiparasitic agent, against filarial parasites was
reported, and various combinations of these 3 drugs have
been evaluated.
A possible additive or synergistic effect of DEC and
ivermectin was reported in Haiti based on a finding that 20
µ g/kg ivermectin given as a clearing dose at day 1, followed
by a single 6 mg/kg dose of DEC at day 5 resulted in higher
efficacy in reducing mf density than DEC alone 1 year after
treatment [50]. The same regimen tested in Brazil produced
the best results among different combinations of the 2
drugs: reduction of microfilaremia to 2.4% of the pretreat-
ment level (100%) at 2 years [51]. In Tahiti, 2 annual single
dose MDAs were conducted using 4 different regimens: (i)
ivermectin 400 µ g/kg plus DEC 6 mg/kg, (ii) ivermectin
400 µ g/kg alone, (iii) DEC 6 mg/kg alone, and (iv) iver-
mectin 400 µ g/kg plus DEC 3 mg/kg [54]. After 1 year,
regimens (i) and (iv) resulted in the same 32% reduction in
mf prevalence, while the reduction was only 11-14% using
regimens (ii) and (iii). As for mf density, the former 2 regi-
mens brought about a 95-96% reduction from the pretreat-
ment level, and the latter 2 regimens 80-82%. To clarify the
effect of combination therapy on adult worms, a single dose
of DEC at 6 mg/kg was co-administered with either 200 µ g/
kg or 400 µ g/kg of ivermectin, and filaria dance sign was
observed with ultrasonography [55]. Interestingly, the
dance sign was evident in all of the 30 nests studied, sug-
gesting that the co-administration interfered with the al-
ready established adulticidal effect of DEC.
Other studies have looked at the combination of alben-
dazole and DEC or ivermectin. A review by Ottesen et al.
(1999) [56] summarized the role of albendazole for lym-
phatic filariasis elimination. Ismail et al. (1998) [57], work-
ing with W. bancrofti, showed more reduction in geometric
mean mf density with a combined single dose of albenda-
zole (600 mg) plus ivermectin (400 µ g/kg) than with a com-
bination of albendazole (600 mg) plus DEC (6 mg/kg) up to
12 months after treatment. At 15 months, however, there
was no significant difference between the two (reduction of
> 98% in both regimens). As for circulating filarial antigen,
the latter combination resulted in significantly more reduc-
tion (77%) than the former at 15 months. A combined sin-
gle dose of albendazole (400 mg) plus DEC (6 mg/kg) re-
duced mean mf density by 85.7-99.6% 12-24 months after
treatment [58-61]. On the other hand, several studies could
not confirm the benefit of albendazole in various combina-
tions with ivermectin/DEC [62-65]. Dreyer et al. (2006)
[66] compared the adulticidal effect of DEC (6 mg/kg)
alone and DEC (6 mg/kg) plus albendazole (400 mg), and
reported that the combination resulted in a much lower ef-
fect on filaria dance sign. The authors concluded that co-
administration appeared to reduce the adulticidal effect of
DEC. Further studies are necessary to confirm or refute
anti-filarial effects of albendazole in combined use with the
other anti-filarials [67].
The role of albendazole in the global program for filar-
iasis elimination has to be emphasized for its “beyond-
filariasis” benefits [55]. The drug is very effective against
intestinal helminths such as Ascaris, Trichuris and hook-
worm, which have inflicted a tremendous burden on the
health of poor people in developing countries. In Haiti, 2
annual single-dose MDAs with DEC (6 mg/kg) and alben-
dazole (400 mg) reduced Ascaris, Trichuris and hookworm
prevalences from 20.9% to 14.1%, 34.0% to 14.6%, and
11.2% to 2.0%, respectively, 9 months after the second
MDA [68]. In India, the same treatment reduced the preva-
lence of Ascaris by 83%, Trichuris by 63% and hookworm
by 69%, 11 months after the second MDA [69]. These
“beyond-filariasis” benefits will not only give the anti-
filariasis campaign a broader public health significance but
also help to improve compliance among people and sustain
the elimination program. The combination of drugs is also
said to be effective in preventing the acquirement of drug
resistance by filarial parasites.
̎ ̑F. Global Programme to Eliminate Lymphatic Filariasis
(GPELF)
f-1. Strategies/activities
The World Health Assembly made a resolution in 1997
to eliminate lymphatic filariasis from the world as a public
health problem by 2020. To execute the resolution, the
GPELF was organized with a main strategy of conducting
annual single-dose MDA for 4-6 years. Under MDA, all
people living in endemic areas with or without filarial infec-
tion are expected to be treated, meaning that the number in
83 endemic countries will reach some 13 billion people.
The drugs used for MDA are the combination of DEC (6
mg/kg) and albendazole (400 mg) in onchocerciasis-free ar-
eas, and ivermectin (200-400 µ g/kg) and albendazole (400
mg) in onchocerciasis-endemic areas of Africa. The reason
for the use of 2 separate regimens is that DEC could cause
severe reactions if administered to Onchocerca-infected in-
dividuals. The biggest barrier to financing the drug supply
was removed by the donation of albendazole and ivermectin
by the 2 pharmaceutical giants. The GPELF has also put
particular emphasis on the care of existing clinical cases of
lymphedema/elephantiasis and hydrocele. Simple proce-
dures for lymphedema management have been established
[70], in which the cure and prevention of bacterial/fungal
infections by maintaining good hygiene of the affected skin
is the basic concept. Daily washing with soap and water,
together with exercise and elevation of the affected limb to
drain accumulated lymph fluid, is the most essential part of
the “care” for which family members and volunteers have
been trained [71].
In the beginning, many researchers/clinicians were
suspicious about the success of such a huge program. Some
rejected the idea outright because they considered filariasis
a low-priority disease. However, a tectonic shift was al-
ready underway: the idea of DALY had changed disease
priority in favor of filariasis that produces permanent or
long-lasting disability, and non-profit activities for the un-
derprivileged by a variety of voluntary groups/citizens had
matured. People suffering from lymphatic filariasis, one of
the world’s most neglected diseases, have gained global at-
tention for the first time in history.
f-2. Achievements
Ottesen et al. (2008) [72] described in detail the results
of 8 years of global effort (2000-2007). More than 740 mil-
lion albendazole tablets and 590 million ivermectin tablets
were donated by the partner drug companies of the GAELF,
while 4.7 billion DEC tablets were purchased by endemic
countries. A minimum of 570 million individuals were
treated in 48 of the 83 endemic countries. In 68 pre-fixed
sentinel sites to monitor treatment effects, 5 rounds of MDA
reduced mf prevalence by ca. 85% and cleared mf in 63%
of the sites. The WHO report in 2008 [8] listed 5 countries
which no longer have active transmission foci, and 2 coun-
tries (China and Korea) where the elimination of filariasis
was declared.
The benefits of the MDAs conducted in 2000-2007 in-
clude the following: 6.6 million newborns were protected
from filarial infection, of whom 1.4 million and 0.8 million
individuals will escape hydrocele and lymphedema, respec-
tively, in their lifetimes; 9.5 million asymptomatic parasite
carriers were protected from developing hydrocele (6.0
mil.) or lymphedema (3.5 mil.). The DALYs averted in 8
years were estimated to reach 32 million, for which US$
190 million was spent to cover MDA-related costs. Thus,
the cost per DALY averted was US$ 5.90 (excluding do-
nated drugs), which is one of the most cost effective pro-
grams in the world [73].
In addition to the benefits of the 2000-07 MDAs relat-
ing to filariasis, 56.6 million children and 44.5 million
women of childbearing age were treated with albendazole
for intestinal parasitic infections, and in onchocerciasis en-
demic countries of Africa, more than 45 million were
treated with ivermectin for various skin diseases caused by
Onchocerca volvulus, scabies mites and lice, although DA-
LYs averted by these treatments were not quantified. It can
readily be said that the global filariasis program has already
established new precedents: collaboration in combating ne-
glected diseases, single-dose treatment for different diseases,
and confidence of local people in maintaining a public
health program, all on a global scale.
f-3. The future
The progress made by the GPELF has been remarkable
so far. However, the elimination program is not necessarily
proceeding satisfactorily in all endemic countries. Prob-
lems arise when compliance to MDAs is not sufficient, pre-
treatment endemicity levels are high, the species of vector
mosquito is an efficient transmitter, MDA drug dosage is
not sufficient (particularly with ivermectin), etc. [74]. A
more serious question will be the endpoint for the elimina-
tion program in each endemic country. The variability of
biological, human-behavioral and socio-economic factors
make it difficult to clarify a threshold at which filariasis
transmission disappears spontaneously. With strong con-
tinuous global cooperation as a precondition, each endemic
country needs to carry out well-organized and effective
MDAs. The drug administration may have to be repeated if
necessary. Vector control measures may become an essen-
tial part of the program in some areas [75]. And it is ex-
pected that mathematical models will play a more important
̎ ̒role in planning future operations [76].
G. Expansion of intervention activities by people:
Community-directed treatment (ComDT)
In many endemic areas where health manpower is run-
ning short, it is difficult to carry out a large scale MDA. In
Okinawa, Japan, in the 1960s, senior high school graduates
living in the endemic areas were trained as “ad hoc” labora-
tory technicians [77]. In Sri Lanka, the MDA in 2003
achieved 80% drug coverage of 9.8 million endemic popu-
lation, and more than half of the drug coverage (55.2%) was
executed by volunteers making door-to-door visits [78].
In West Africa, when the Onchocerciasis Control Pro-
gramme started employing annual mass treatment with iver-
mectin, they faced the same problem of manpower shortage.
Then in 1995, WHO/TDR conducted a landmark study in 5
African countries to clarify how well local people can plan
and execute the distribution of ivermectin by themselves
[79]. In the study, 2 different treatment schemes were com-
pared: community-designed treatment and program-
designed treatment. In the former, after a minimal essential
health education/information session, the community was
invited to decide who in the community would be drug dis-
tributers and when and how the drugs would be distributed,
while in the latter, experienced program staff pre-designed
the criteria for selecting drug distributers and detailed pro-
cedures for drug distribution. The results were rather unex-
pected: the former achieved as good a treatment coverage as
the latter. This was a clear indication that local people can
be a reliable player in public health activities. A similar
study with lymphatic filariasis followed in Ghana and
Kenya [80], where community-directed treatment with
some input from health services (ComDT/HS) was com-
pared with the treatment planned and executed by the regu-
lar care system (HST). The results: ComDT/HS achieved a
high treatment coverage of 75.7% - 88.0%, whereas HST
obtained only 43.6% - 46.5%.
The African Programme for Onchocerciasis Control
(APOC), which was set up in 1995 covering 16 countries,
adopted the idea of community-designed treatment from the
above 1995 TDR study and implemented the community-
directed treatment with ivermectin (CDTI). The program
was so successful in reducing the burden of onchocerciasis
that, in the year 2007, close to 1 million DALYs could be
averted [81]. For CDTI, “community drug distributers”
(CDDs) play an essential role. After training, they take a
census, distribute drugs, monitor adverse reactions and keep
records. In 2006, there were 429,385 trained CDDs in
APOC countries. These batteries of manpower with health
care knowledge have become involved as a matter of course
in other intervention programs. In Nigeria, successful inte-
gration of insecticide-treated bed net distribution for ma-
laria control with lymphatic filariasis/onchocerciasis MDA
was reported [82]. WHO/TDR, in 2005, launched a study
to investigate whether the concept and experience of CDTI
can be applied to other interventions such as delivering vita-
minA supplement, insecticide treated nets, DOTS treatment
for tuberculosis, and home management of malaria. The re-
sults showed that all 5 interventions (including CDTI) could
be done simultaneously by the community [83].
Community-directed treatment, which was invented as
a measure necessary to conduct a large scale MDA for on-
chocerciasis in areas where health infrastructures were poor,
has been transformed into a new sustainable way of deliver-
ing therapeutic and preventive measures for rural people
suffering from a variety of neglected diseases. The MDAs
for lymphatic filariasis, which have been conducted side by
side with APOC, can be expected to strengthen the new de-
velopment synergistically.
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